Objectives: Our study shows how the COVID-19 pandemic in Israel affected the circulation of Human Metapneumovirus (HMPV) during 2021 in comparison to previous years (2019-2020) as well as subtypes that were in circulation in Israel. Our results emphasize the need for developing an HMPV vaccine that will be efficient in children, more so now than before in light of the ongoing pandemic, and to prevent a possible pandemic from occurring in the future.
Methods: We collected and analysed 15,094 respiratory samples from patients of all ages, during the years 2019 to 2021 at the Sheba Medical Centre in Israel, and performed RT-PCR analysis of these samples. Additionally, we utilized whole genome sequencing to characterize the subtypes of HMPV circulating in Israel from 2019 to 2021.
Results: Before the emergence of COVID-19, HMPV usually peaked in the winter-months, then declined throughout the year. However, in 2021 with the lockdown policy and the government campaign of vaccination, we saw higher rates of HMPV infections, particularly in children, and mainly of subtype B1.
Conclusions: The COVID-19 pandemic influenced the repertoire of seasonal respiratory viruses, human Metapneumovirus in particular, with higher infection rates seen mainly in children.